Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (2016 - 2022)

Historic Shares Outstanding for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q2 2022 value amounting to $28.5 million.

  • Viridian Therapeutics, Inc.\DE's Shares Outstanding rose 23063.49% to $28.5 million in Q2 2022 from the same period last year, while for Jun 2022 it was $28.5 million, marking a year-over-year increase of 23063.49%. This contributed to the annual value of $23.9 million for FY2021, which is 46542.76% up from last year.
  • As of Q2 2022, Viridian Therapeutics, Inc.\DE's Shares Outstanding stood at $28.5 million, which was up 23063.49% from $27.2 million recorded in Q1 2022.
  • Viridian Therapeutics, Inc.\DE's 5-year Shares Outstanding high stood at $28.5 million for Q2 2022, and its period low was $2.1 million during Q4 2018.
  • Its 5-year average for Shares Outstanding is $11.2 million, with a median of $5.7 million in 2020.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding skyrocketed by 1304.31% in 2019 and then surged by 46542.76% in 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Outstanding (Quarter) stood at $2.1 million in 2018, then increased by 13.04% to $2.3 million in 2019, then surged by 82.05% to $4.2 million in 2020, then soared by 465.43% to $23.9 million in 2021, then increased by 18.98% to $28.5 million in 2022.
  • Its last three reported values are $28.5 million in Q2 2022, $27.2 million for Q1 2022, and $23.9 million during Q4 2021.